{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T18:29:56Z","timestamp":1648578596552},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.nefro.2016.01.013","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T10:18:48Z","timestamp":1464949128000},"page":"333-338","source":"Crossref","is-referenced-by-count":0,"title":["Recomendaciones y sugerencias a 4 preguntas clave en nefropat\u00eda l\u00fapica: Extracto de la gu\u00eda de pr\u00e1ctica cl\u00ednica 2015"],"prefix":"10.1016","volume":"36","author":[{"given":"Mar\u00eda Adoraci\u00f3n","family":"Mart\u00edn-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rivera Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Frutos Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda M.","family":"Trujillo-mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2016.01.013_bib0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefro.2016.01.013_bib0215","first-page":"140","article-title":"Insu\ufb01ciencia renal aguda en la nefritis l\u00fapica","volume":"12","author":"Frutos","year":"1992","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefro.2016.01.013_bib0220","unstructured":"Grupo de Trabajo de la Gu\u00eda de Pr\u00e1ctica Cl\u00ednicas sobre Lupus Eritematoso Sist\u00e9mico. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre Lupus Eritematoso Sist\u00e9mico. Ministerio de Sanidad, Servicios Sociales e Igualdad. Servicio de Evaluaci\u00f3n del Servicio Canario de la Salud; 2015. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica en el SNS (NIPO 680-15-083-4)"},{"key":"10.1016\/j.nefro.2016.01.013_bib0225","first-page":"525","article-title":"Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares","volume":"13","author":"Kong","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0230","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3899\/jrheum.120537","article-title":"Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: A prospective observational study","volume":"39","author":"Fischer-Betz","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0235","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","article-title":"Prednisone in lupus nephritis: How much is enough?","volume":"13","author":"Ruiz-Irastorza","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefro.2016.01.013_bib0240","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1191\/0961203304lu1063oa","article-title":"Risk of ovarian failure and pregnancy outcome in patients treated with intravenous cyclophosphamide pulse therapy","volume":"13","author":"Park","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: The ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefro.2016.01.013_bib0250","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefro.2016.01.013_bib0255","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0260","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1093\/ndt\/gfp235","article-title":"Value of the RIFLE classification for acute kidney injury in diffuse proliferative lupus nephritis","volume":"24","author":"Chen","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.01.013_bib0265","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1177\/0961203311417035","article-title":"Acute kidney injury in Chinese patients with lupus nephritis: A large cohort study from a single center","volume":"20","author":"Zhu","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ki.2009.136","article-title":"Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis","volume":"76","author":"Yu","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2016.01.013_bib0275","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000350756","article-title":"Mycophenolate as maintenance therapy for lupus nephritis with impaired renal function","volume":"37","author":"Rivera","year":"2013","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.nefro.2016.01.013_bib0280","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1159\/000337916","article-title":"Mycophenolate as induction therapy in lupus nephritis with renal function impairment","volume":"35","author":"Rivera","year":"2012","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.nefro.2016.01.013_bib0285","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: A subgroup analysis of the Aspreva Lupus Management Study","volume":"61","author":"Walsh","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2016.01.013_bib0290","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus 2 regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.nefro.2016.01.013_bib0295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1191\/0961203304lu510xx","article-title":"Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares","volume":"13","author":"Kong","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0300","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppresive therapy","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefro.2016.01.013_bib0305","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.20364","article-title":"Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis","volume":"50","author":"Mok","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nefro.2016.01.013_bib0310","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.01.013_bib0315","first-page":"681","article-title":"Clinical status of patients after 10 years of lupus nephritis","volume":"305","author":"Moroni","year":"1992","journal-title":"Q J Med"},{"key":"10.1016\/j.nefro.2016.01.013_bib0320","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/ki.1996.528","article-title":"Nephritic flares are predictors of bad long-term renal outcome in lupus nephritis","volume":"50","author":"Moroni","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2016.01.013_bib0325","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.01.013_bib0330","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0961203309106602","article-title":"Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine","volume":"18","author":"Mok","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0335","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1046\/j.1523-1755.2002.00280.x","article-title":"Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis","volume":"61","author":"Mosca","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2016.01.013_bib0340","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/rheumatology\/ker514","article-title":"Anti-malarials exert a protective effect while mestizo patients are at increased risk of developing SLE renal disease: Data from a Latin-American cohort","volume":"51","author":"Pons-Estel","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefro.2016.01.013_bib0345","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9343(88)80366-8","article-title":"Discontinuation of therapy in diffuse proliferative lupus nephritis","volume":"85","author":"Ponticelli","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.nefro.2016.01.013_bib0350","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2215\/CJN.03640412","article-title":"Lupus nephritis: Maintenance therapy for lupus nephritis--do we now have a plan?","volume":"8","author":"Lenz","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0355","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0360","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2016.01.013_bib0365","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefro.2016.01.013_bib0370","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/0961203308100481","article-title":"European consensus statement on the terminology used in the management of lupus glomerulonephritis","volume":"18","author":"Gordon","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0375","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/ard.2006.067835","article-title":"Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus","volume":"66","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nefro.2016.01.013_bib0380","first-page":"62","article-title":"Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: A prospective cohort study","volume":"31","author":"Fei","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0385","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multitarget therapy","volume":"19","author":"Bao","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0390","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/0961203313502864","article-title":"Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: A 12-month prospective study","volume":"22","author":"Mok","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.nefro.2016.01.013_bib0395","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefro.2016.01.013_bib0400","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts","volume":"11","author":"D\u00edaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.nefro.2016.01.013_bib0405","first-page":"1","article-title":"Diagnosis and treatment of lupus nephritis. Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (SEN)","volume":"32","author":"Ruiz Irastorza","year":"2012","journal-title":"Rev Nefrol"},{"key":"10.1016\/j.nefro.2016.01.013_bib0410","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699516300297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699516300297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T12:00:19Z","timestamp":1536667219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699516300297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0211699516300297"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2016.01.013","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}